Mannkind Corp

  • Earnings Score
  • Safety Score
  • Market Cap $1.86B
  • Debt $230.00M
  • Cash $62.37M
  • EV $2.02B
  • FCF $28.87M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$21.57M
EBIT$53.95M
ROA12%
FCF$28.87M
Equity-$209.93M
Growth Stability1
PE86.02
PB-8.84
P/FCF64.25
P/S6.94
Price/Cash0.03
Debt/Equity-1.1
Debt/FCF7.97
Net Margins10%
Gross Margins93%
Op. Margins20%
Earnings CAGR-2%
Sales Growth YoY37%
Sales Growth QoQ-3%
Sales CAGR20%
Earnings Stability0.07
Earnings Growth YoY571%
Earnings Growth QoQ-673%
Sales CAGR 5Y39%
Earnings CAGR 3Y77%
Sales CAGR 3Y77%
Market Cap$1.86B
Revenue$267.20M
Assets$464.20M
Total Debt$230.00M
Cash$62.37M
Shares Outstanding272.81M
EV2.02B
Earnings Score6%
Safety Score51%
Working Capital255.56M
Current Ratio4.54
Gross Profit$248.47M
Shares Growth 3y4%
Equity Growth QoQ-7%
Equity Growth YoY-17%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

SEC Filings

Direct access to Mannkind Corp (MNKD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Mannkind Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Mannkind Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -2%
Stability 7%
loading chart...

Mannkind Corp Discounted Cash Flow

Fully customizable DCF calculator online for Mannkind Corp.

= $289M
012345678910TV
fcf$29M$29M$29M$29M$29M$29M$29M$29M$29M$29M$29M$289M
DCF$26M$24M$22M$20M$18M$16M$15M$13M$12M$11M$111M
Value$289M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins--72%-999%-312%-82%-88%-107%-88%-6%10%
ROA--273%117%-128%-71%-48%-44%-15%-22%2%12%
ROE-105%-68%55%50%27%32%39%35%5%-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF--1.51-1.25---1.38-4.25-3.94-3.16-32.617.97
Debt over Equity-1.35-0.29-0.54-0.98-0.65-0.66-0.68-1.38-1.11-1.11-1.1
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth----93%137%126%3%16%32%99%39%
Earnings YoY growth-86%-134%-193%-26%-40%10%41%8%-86%-
Equity YoY growth-375%-48%17%-18%9%-5%16%20%-2%-
FCF YoY growth-237%17%--139%-68%153%21%-91%-